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Polysaccharide storage myopathy (PSSM) is a novel glycogenosis in horses characterized by abnormal glycogen accumulation in skeletal
muscle and muscle damage with exertion. It is unlike glycogen storage diseases resulting from known defects in glycogenolysis, glycolysis, and
glycogen synthesis that have been described in humans and domestic animals. A genome-wide association identified GYS1, encoding skeletal
muscle glycogen synthase (GS), as a candidate gene for PSSM. DNA sequence analysis revealed a mutation resulting in an arginine-to-histidine
substitution in a highly conserved region of GS. Functional analysis demonstrated an elevated GS activity in PSSM horses, and haplotype analysis
and allele age estimation demonstrated that this mutation is identical by descent among horse breeds. This is the first report of a gain-of-function
mutation in GYS1 resulting in a glycogenosis.
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modern breeds have been established by selection for a variety
of athletic, physical, and behavioral traits. In horses, as in
other animal species, line breeding to propagate desirable traits
has coincidentally also propagated deleterious traits. One such
undesirable trait is polysaccharide storage myopathy (PSSM)
[1–12], a debilitating and potentially life-threatening glycogen
storage disease that occurs in several genetically diverse
breeds of horses [12–15] (Fig. 1a). Clinical findings consistent
with PSSM were first reported in the early 1900s in working
draft horses that developed exertional rhabdomyolysis when☆ Sequence data from this article have been deposited with the EMBL/
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doi:10.1016/j.ygeno.2008.01.011returning to work after several days of rest [2,6,16]. However,
PSSM was not recognized as a skeletal muscle glycogenosis
until 1992 [2]. Today, as many as 36% of draft horses [12] and
10% of Quarter Horses [17] have PSSM. The phenotypic
expression of PSSM ranges from muscle atrophy and
progressive weakness in draft horse breeds to muscle soreness
and gait abnormalities in warmblood breeds and acute
exertional rhabdomyolysis in Quarter Horses. The severity of
clinical signs in PSSM ranges from muscle cramping and
stretching out (Fig. 1b) to severe muscle pain and myoglo-
binuria and occasionally the complete inability to rise (Fig.
1c). Although PSSM is clinically well recognized and com-
mon, its metabolic basis has remained a mystery for over a
hundred years.
All horses with PSSM accumulate excess glycogen as well as
abnormal amylase-resistant polysaccharide (Fig. 2) in type 2A
and type 2B skeletal muscle fibers. [9] The disease has been best
characterized in Quarter Horses, in which a familial relationship
Fig. 1. Diversity of phenotypes and clinical signs of horses affected with PSSM. (a) A quarter horse on the left (60 in. tall at height of shoulder) and a Belgian draft
horse (72 in. tall at height of shoulder), both with PSSM. (b) A quarter horse with typical signs of muscle cramping accompanying an episode of exertional
rhabdomyolysis. (c) A quarter horse severely afflicted with exertional rhabdomyolysis that can only stand for a few minutes with assistance from a sling.
459M.E. McCue et al. / Genomics 91 (2008) 458–466[3], enhanced insulin sensitivity and blood glucose uptake [10],
and myofiber energy deficit with submaximal exercise [11] have
been demonstrated. Although glycogenolytic and glycolytic
defects are the most common cause of glycogenoses in humans,
PSSM horses have normal glycogenolytic and glycolytic enzyme
activities and are able to utilize glycogen and produce lactate with
anaerobic exercise [2,18]. Thus, PSSM appears to be a unique
animal model of abnormal muscle glycogen metabolism [18,19]
that may provide insight into myocyte carbohydrate metabolism
and the genetic basis of uncharacterized glycogenoses in humans.
The complexity of potentially defective pathways including in-
sulin signaling, skeletal muscle glucose uptake, and glycogen
metabolism dictated that a positional cloning approach should be
utilized to identify positional candidate genes [10,18,20].
Results
Genome-wide association analysis
One hundred five microsatellite (MS) markers distributed on
all 31 equine autosomes were genotyped on an initial population
of 48 related PSSM and 48 unrelated control Quarter Horses.
The 48 related PSSM Quarter Horse cases were selected from
an extended pedigree and all traced back to a single commonFig. 2. Photomicrographs of skeletal muscle from a horse with PSSM. (a) Periodic
normal horse demonstrating the presence of normal glycogen. (b) PAS staining of
inclusions of abnormal polysaccharide in multiple fibers. (c) Amylase digestion and
glycogen has been digested, whereas the abnormal polysaccharide is amylase resistaancestor within seven generations, thus increasing the extent of
the shared chromosomal segment surrounding the mutation and
improving the power to detect association (see methods and
Supplementary Fig. 4 for population structure). χ2 tests for
association gave a range of p values from 1.9×10−5 to 0.97 for
the comparison of allele frequencies between the PSSM and the
control groups (Supplementary Fig. 1). Two markers on two
different chromosomes had p values b0.001. One of these
markers, NVEQ018 on ECA10p gave a p value of 1.9×10−5,
and its allele distribution showed that 23/48 of the affected
horses possessed an allele that was virtually absent (2/48) in the
controls (Fig. 3).
Eight additional ECA10p MS were then genotyped to define
an approximately 10-Mb interval that was highly associated with
PSSM (p=2.1×10−4 to 1.9×10−7) (Fig. 3). To rule out spurious
association due to the relatedness of the affected and control
cohorts and thus dependence of the observations in the χ2
analysis, and to narrow the candidate chromosomal region, a
follow-up population of 52 PSSM and 44 control Quarter Horses
was genotyped. PSSM cases in the follow-up cohort were
chosen on the basis of not sharing a common ancestor with the
initial case cohort within five generations. The two markers with
p values b2.0×10−5 in this follow-up population (COR015
and SCGV030) spanned an approximately 3-Mb region highlyacid-Schiff (PAS) staining of a cross section of semitendinosus muscle from a
the same muscle from a horse with PSSM showing crystalline PAS-positive
PAS staining of a serial section of muscle from the PSSM horse in (b). Normal
nt.
Fig. 3. ECA10p p values. Map of ECA10p and p values of association of MS marker alleles with PSSM in the initial and follow-up case and control cohorts. From left
to right: idiogram of ECA10p with FISH-anchored loci [21], radiation hybrid map of ECA10p with comparative mapping of loci to HSA19 [21], p values for χ2
comparison of MS allele frequencies in the initial population and the follow-up population. The GYS1 gene at the 54.1 Mb position on HSA19 is indicated.
460 M.E. McCue et al. / Genomics 91 (2008) 458–466associated with PSSM (Fig. 3). The p values for these two
markers in the combined population of 100 cases and 92 controls
were 1.0×10−14 and 2.0×10−8.
The horse–human comparative map indicates that the region
of ECA10p encompassed by COR015 and SCGV030 is homol-
ogous to human chromosome 19 (HSA19), from position 51.9
to 54.6 Mb [21]. Of the positional candidates in this region of
HSA19, only the GYS1 gene at 54.1 Mb is known to play a
direct role in carbohydrate metabolism. GYS1 encodes the
skeletal muscle isoform of glycogen synthase (GS) that is
expressed in skeletal muscle and nonhepatic tissues [22]. GS
catalyzes the addition of single glucosyl residues from UDP-glucose onto a glycogen polymer using an α 1→ 4 glycosidic
linkage [23] and is the rate-limiting step in glycogen synthesis
[24].
Identification of a candidate causal mutation
The GYS1 protein coding sequence, as well as 5′and 3′
untranslated sequences from a PSSM and a control Quarter
Horse, was PCR amplified and sequenced from skeletal muscle
cDNA or genomic DNA. The PSSM horse sequenced was
selected because it was homozygous at both the COR015 and the
SCGV030 loci and was likely to be homozygous for a potential
Fig. 4. Glycogen synthase amino acid alignment. Multiple amino acid alignment of glycogen synthase 1 (skeletal muscle isoform) and glycogen synthase 2 (liver
isoform). Residue 309 at the site of the GYS1 PSSM mutation and the surrounding amino acids are highly conserved across species and across both GS isoforms.
Fig. 5. Glycogen synthase activity. Mean GS activity in the presence and ab-
sence of its allosteric activator, glucose 6-phosphate (G6P). ⁎Significant dif-
ference between PSSM and controls.
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controls used for the genome scan. A single polymorphism was
identified, in which a G-to-A base substitution changes the
normal arginine (R) at codon 309 (CGT) to a histidine (H) (CAT)
in PSSM-affected Quarter Horses. Sequence analysis of GYS1
exon 6 from genomic DNA was performed in six additional
severely affected and six control horses. Two of the PSSM-
affected horses were homozygous and four were heterozygous
for the histidine mutation, while the six control horses were all
homozygous for the normal arginine allele. Multiple alignment
of the amino acid sequence in this region demonstrated that
arginine 309, as well as the surrounding amino acids (305-
QEFVRGHFYGH-314), are highly conserved in both the GYS1
(muscle) and the GYS2 (liver) forms of GS (Fig. 4).
Glycogen synthase activity in PSSM
Glycogen synthase assays on muscle homogenates were
performed. The mean GS activity was higher in PSSM than in
control muscle in both the presence and the absence of the
allosteric activator glucose 6-phosphate (G6P) ( p=0.03 and
0.04, respectively) (Fig. 5). The −/+ G6P ratio was not sig-
nificantly different between PSSM and control horses ( p=0.09;
mean=0.06 and 0.03 in PSSM and control, respectively). The
low −/+ G6P ratio suggests that the GS present in the skeletal
muscle homogenates was highly phosphorylated [25].
GYS1 allele frequency in Quarter Horses
Ninety-nine PSSM Quarter Horses used in the whole
genome association analysis were genotyped for the Arg309His
mutation; 72 were heterozygous and 5 were homozygous for the
H allele. Surprisingly, 22 PSSM horses were homozygous for
the normal R allele. Eighty-eight of the 92 control Quarter
Horses were homozygous normal and 4 were heterozygous for
the H allele. Based on these genotypes, penetrances of the H/H
and R/H genotypes are 1.0 and 0.95, respectively. However, agluteal muscle biopsy is not a 100% sensitive diagnostic test,
and the 4 control horses that were heterozygous for the H allele
may have been false negatives and may represent phenotypic
error [17]. Segregation of the H allele with PSSM was con-
firmed in a resource pedigree (Supplementary Fig. 2).
The population of PSSM horses without the GYS1 H allele
suggests either that the G-to-A substitution is not the causative
mutation or that the PSSM-affected horses without the G-to-A
substitution are phenocopies. Sequencing from 480 bp upstream
of the predicted promoter region through exon 1, the entire coding
sequence, and the 3′ UTR (301 bp) did not detect any additional
sequence differences between affected and control horses. Fur-
thermore, association analysis using the same ECA10p MS
markers excluded this chromosomal locus andGYS1 as the cause
of abnormal polysaccharide accumulation in GYS1 R/R PSSM
Quarter Horses (Supplementary Fig. 3). This strongly suggested
that a second non-GYS1 glycogenosis exists that also produces
exertional rhabdomyolysis and skeletal muscle polysaccharide
accumulation in Quarter Horses.
Fig. 6. Conserved SNP haplotypes among breeds containing the GYS1A (PSSM) allele. The minimally conserved haplotype in all breeds is highlighted and the length
in kilobases in different breeds is indicated on the right. The kilobases in the horizontal position are the relative positions of each SNP within the 2-Mb contig
containing the GYS1 gene. The GYS1 A allele producing the Arg309His GS mutation is indicated at the 819-kb position as the PSSMSNPEXON6 SNP.
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Despite similarities in histopathologic findings in different
breeds, there is variability in clinical findings in PSSM across
breeds [5]. Seven hundred fifty horses from diverse breeds
diagnosed with PSSM on the basis of abnormal polysaccharide
in skeletal muscle were genotyped for the GYS1 mutation. The
H allele was found in either heterozygous or homozygous form
in 356 horses from 15 different breeds, including Quarter
Horses, Paint Horses, Appaloosa horses, five draft horse breeds,
three warmblood breeds, and the Morgan, Mustang, and Rocky
Mountain horse breeds, as well as mixed-breed horses and
warmblood horses of unspecified breed.
Haplotype analysis and allele age
If the G-to-A GYS1 mutation is identical by descent in
multiple horse breeds, it suggests that it was present in the
domestic horse population before the establishment of the
diverse breeds known today, and it has been passed from
established breeds to newer breeds by admixture at the time of
new breed creation. Seven hundred sixty-seven horses from the
breeds containing the Arg309His mutation were genotyped
for 45 SNP markers in the 2-Mb region surrounding GYS1.
Missing genotypes and haplotype phase were inferred using
fastPHASE 1.2 [26], and the minimally conserved haplotype
was determined using Haploview 4.0RC2 [27]. All chromo-
somes with the GYS1A allele had a single conserved haplotype
(Fig. 6). This conserved haplotype suggests that the A allele is
identical by descent in all horse breeds. The conserved hap-
lotype was the shortest in Belgian draft horses (351 kb),consistent with the earlier origin of the Belgian breed and more
decay of linkage disequilibrium (LD) around the mutation.
Quarter Horses, Paint Horses, and Appaloosas shared a larger
conserved segment (642 kb) likely due to the more recent origin
of these breeds.
The mean allele age of the GYS1 mutation, estimated with
DMLE+ 2.0 [28], was 159 generations, median allele age was
163 generations, and mode was 153 generations. The range of
generations with significant frequencies ( pb0.05) was 140 to
189, and 90% of iterations fell between 144 and 178 gene-
rations. With the mean generational interval in horses estimated
to be approximately 8 years, we conclude that this mutation
likely originated between 1200 and 1500 years ago [29], prior to
the separation of the modern breeds known today.
Discussion
Our results are consistent with the hypothesis that the PSSM
phenotype in horses is due to a dominant gain-of-function
mutation in theGYS1 gene that results in enhanced activity and/or
poor regulation of the mutant His309 enzyme. Support for a gain
of function in GS resulting in a glycogenosis in mammals comes
from mice overexpressing a rabbit skeletal muscle GS that is not
inactivated by protein kinase catalyzed phosphorylation [30].
Similar to PSSM horses, these mice accumulate excessive
abnormal polysaccharide in the cytoplasm of skeletal myocytes,
which disrupts normal myofibrillar ultrastructure [30–32]. The
iodine absorption spectra of the abnormal polysaccharide in both
GS overexpressing mice and PSSM horses is shifted to higher
wavelengths, consistent with decreased branched structure of
glycogen [11]. Finally, when exercised to exhaustion the mice
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gerated increase in blood lactate, suggesting an increased rate of
anaerobic glycogenolysis and glycolysis similar to that in PSSM
horses [32].
The action of GS is the rate-limiting step in glycogen syn-
thesis; therefore its enzymatic activity is tightly controlled. GS
activity is not extensively regulated through GYS1 gene ex-
pression in mammals because of the need to change rapidly
from glycogen synthesis to degradation [22]. Gain-of-function
mutations are most commonly caused by increased expression
of the mutant protein due to mutation in the promoter region of
the gene. However, the GYS1 mutation identified in PSSM-
affected horses occurred in the coding sequence of exon 6,
altering codon 309, and sequencing of the promoter and the 5′
UTR of the GYS1 from PSSM-affected horses did not
demonstrate any sequence polymorphism. Furthermore, over-
expression of GS in mammalian in vitro and in vivo systems, or
in yeast systems, fails to result in glycogen accumulation, due to
phosphorylation and inactivation of the overexpressed GS
enzyme [24,30,33,34]. Thus it is more likely that the glycogen
accumulation in PSSM horse muscle is due to the Arg309His
mutation and results from enhanced activity and/or poor re-
gulation of the mutant enzyme.
The interaction between allosteric activation and covalent
modification of GS by protein kinases may be best described by
a three-state model [25]. In this model, phosphorylated GS in
the absence of G6P is in a low activity state (state I) and de-
phosphorylated GS in the absence of G6P is in an intermediate
activity state (state II). Phosphorylated enzyme (state I) requires
near saturation with G6P to reach a high activity state (state III),
whereas dephosphorylated GS (state II) is converted to a high
activity state (state III) by relatively low concentrations of G6P
[25]. The increased activity of GS both in the presence and in
the absence of G6P suggests that the Arg309His enzyme may be
constitutively active in PSSM horses. However, data obtained
from muscle homogenates make it difficult to determine if the
increased GS activity is due to higher inherent enzyme activity,
decreased response to phosphorylation, or altered sensitivity to
allosteric activation by G6P.
The Arg309His mutation in PSSM horses occurs in a highly
conserved region of GS. The importance of this residue and the
highly conserved surrounding region has been demonstrated in
both glycosyltransferase-3 (GT-3, mammalian and yeast) and
glycosyltransferase-5 (GT-5, bacterial) families of GS. Muta-
tion of the homologous residue in Escherichia coli (Lys277)
results in enzyme inactivation [35], while mutation of the
adjacent residue in yeast (Gly310) results in enhanced activity
[34]. Despite clear evidence that this region of the GS enzyme
is important to overall activity, the mechanism by which an
Arg309His mutation results in alteration of GS function in
eukaryotes is unclear since the crystal structure has not been
solved for any member of the GT-3 family and this region has
not been well studied by mutagenesis in GT-3 GS. However,
residues 305–314 are not among the homologous highly con-
served mammalian GT-3 residues implicated in glucosyl do-
nor substrate binding [25,36–43] or catalytic activity [34–36,
40,44].Constitutively active GS in PSSM could result from altered
regulation by phosphorylation or enhanced sensitivity to al-
losteric activation by G6P. Residue 309 is distant to the known
carboxyl-and amino-terminal phosphorylation sites in GT-3 GS,
making it unlikely that it directly inhibits phosphorylation;
however, this does not rule out the mutation from causing re-
sistance to negative regulation due to inappropriate response to
phosphorylation, as observed in a Gly298Asp yeast mutant
(Gly298 in yeast GS is analogous to Gly310 in mammalian GS)
[34]. Altered enzyme activity in response to both negative re-
gulation by phosphorylation and positive regulation by G6P
could also potentially be due to the interaction of residues 305–
314 with the C-terminal arginine-rich cluster (R578A/R579A/
R581A and R585A/R587A/R590A), a critical region of the
GS enzyme, which may act as a molecular switch allowing
GS to toggle between states I, II, and III [25,36,45,46]. The
Arg309His mutation could therefore potentially interfere with
the metabolic switch, resulting in GS being continuously in an
active form. Definitive evidence for this mutation altering the
regulation of GS would necessitate further in vitro study of
Arg309His enzyme kinetics.
GYS1 H allele frequencies range from 0.035 to 0.350 in
different breeds, which is surprisingly high considering that it is
associated with a dominantly inherited neuromuscular disease.
The high prevalence of this mutation in modern horse breeds may
be due to the inadvertent breeding of affected individuals that
were not recognized as having a deleterious genetic disease.
Clinical signs of PSSM can readily be ameliorated if horses re-
ceive consistent daily exercise and limited starch intake [4]. Thus,
over most of the past 1200 years, when horses were used on a
daily basis for work and transportation, and feed could be scarce,
the GYS1 mutation might not have conferred a selectional dis-
advantage. However, in recent times horses have increasingly
become companions that are exercised less frequently, housed in
small spaces, and fed high starch concentrates. In this manage-
ment scenario, horses with the GYS1 H allele are more likely to
develop muscle pain associated with PSSM [6]. It is conceivable
that the GYS1 mutation may have previously conferred a
selectional advantage due to promotion of an increased skeletal
muscle glycogen content when feed sources were scare.
To date, no other naturally occurring gain-of-function mu-
tations in GYS1 have been shown to cause a glycogen storage
disease in any mammalian species. The related GYS2 gene,
expressed in liver, has several known mutations that reduce GS
enzyme activity and hepatic glycogen content, leading to fasting
hypoglycemia [47]. Recently, a mutation in the human GYS1
gene resulting in a stop codon in exon 11, a recessively inherited
cardiac and skeletal muscle glycogen deficiency, hypertrophic
cardiomyopathy, and reduced exercise tolerance, has been
described [48]. However, the dominantly inherited PSSM GYS1
mutation appears to result in an increased GS activity in skeletal
muscle, making it a new form of glycogen storage disease. It
may be useful to examine GYS1 as a candidate gene for the
significant fraction of human glycogen storage myopathies with
as yet undetermined molecular bases [49].
Horses are particularly useful for the study of metabolic
myopathies as they are typically superb athletes bred for speed or
464 M.E. McCue et al. / Genomics 91 (2008) 458–466endurance, and disturbances in any pathway involving energy
metabolism or muscle function are readily apparent since they
are not provided the option of being sedentary. Further under-
standing of the mechanism responsible for altered glycogen
and glucose metabolism in the GYS1 and non-GYS1 forms of
equine PSSM may also provide new insights into normal and
abnormal regulation of muscle glycogen metabolism and the
development of exertional rhabdomyolysis.
Methods
Genome-wide association analysis
PSSM-positive cases were selected from biopsy submissions to the Neu-
romuscular Disease Laboratory at the University of Minnesota as well as from a
population of Quarter Horses identified in a previous prevalence study [50]. Case
criteria for a positive diagnosis of PSSM included: (1) the presence of periodic
acid-Schiff (PAS)-positive inclusions of polysaccharide in gluteal or semimem-
branosus muscle fibers that are typically amylase resistant and (2) 1.5 to 2 times
normal muscle glycogen levels and/or (3) a clinical history of exertional rhab-
domyolysis. Control Quarter Horses were also selected from horses biopsied in
the prevalence study [50]. Control criteria included: (1) a normal gluteal muscle
biopsy that verified the absence of abnormal PAS staining, (2) normal glycogen
levels, and (3) no history of neuromuscular disease.
All horses (cases and controls) with registry information were tracked to the
original breed founders (10–20 generations) and pedigrees were analyzed to
determine the level of relatedness among individuals. Extended family groupings
consisting of several individuals tracing back to a common ancestor within a
short (2–8) generational interval were identified.
For the initial genome-wide association study the goal was to maximize the
length of LD and minimize locus and genotypic heterogeneity in the study
population, thus increasing the power to detect association [51]. This was
accomplished by selecting 48 PSSM-affected horses from the extended families
identified in the pedigree analysis. Because the PSSM horses were closely
related, LD was maximized; minimal recombination would occur between MS
markers flanking the founder PSSM locus. Forty eight PSSM cases were
selected from three extended families identified in the pedigree analysis
(Supplemental Fig. 4). To avoid false inflation of association due to sampling of
closely related individuals we did not include individuals that shared more
genetic material than second cousins [52]. Control Quarter Horses were not
related to the case cohort and were not more closely related than third cousins.
Sample sizes for the initial genome scan were estimated using a genetic
power calculator using the following data [53]: Disease prevalence was set at
0.06 [50], high-risk allele frequency (A) at 0.04 (expected frequency of the
PSSM mutation in the population if it is inherited as a dominant disease trait
based on a conservative estimate of 6% prevalence in the quarter horse pop-
ulation); Aa and AA genotypic relative risks were set at 90 and 95, respectively.
To estimate D′ and marker high-risk allele frequency for power calculations,
previously generated genotype data from 42 markers across seven different
chromosomes from 96 PSSM and control Quarter Horses were analyzed [20].
The mean D′ value for marker pairs with significant allelic association was 0.47
and the mean allele frequency across all alleles of all markers was 0.15. There-
fore, D′ was estimated at 0.47, and high-risk allele frequency for the marker
allele was set at 0.15. Based on these criteria 41.85 cases and an equal number of
controls were required for 85% power with a 5% type I error rate ( p=0.05),
which is in agreement with other published calculations [54].
The initial 105 MS markers genotyped were selected from a group of markers
known to be highly heterozygous in several breeds and were distributed across all
31 autosomes. DNA samples from case and control cohorts were genotyped for
each MS marker using a Beckman CEQ8000 automated DNA fragment analyzer.
The genotypes for each of the MSs were used to compare allele frequencies in the
case and control cohorts. The number of alleles of each size detected in each cohort
was counted (n horses×2 alleles/horse =2n total alleles), and allele frequency in
each cohort was determined. Minor alleles, defined as any allele with a frequency
less than 10% in the entire study population (cases and controls), were summed for
statistical analysis. Case and control cohort allele frequencies were compared withPearson'sχ2 test of independence to determine if there was a significant difference
between the allele distribution in the two cohorts [52].
Identification of a candidate causal mutation
The entire equine GYS1 DNA sequence was assembled from the NCBI trace
files derived from the Broad Institute equine whole-genome 7×shotgun sequence.
The predicted equine GYS1 sequences were used to design primers for PCR
amplification and sequencing. The 5′ UTR and exon 1 were PCR amplified from
genomic DNA with two primer pairs (5′-ACAGAGCTGAGGGCCAATC/5′-
CCGGCTCCCTGTTACTCAAG and 5′-AAAGATCTCTGTGCTCCCTCA/5′-
GGCCCTGCAGTGTAACCTT). Exon 16 and the 3′ UTR were PCR amplified
from genomic DNAwith two primer pairs (5′-GGGATGTGGCTCAGAGACTG/
5′-TAGCGGTAGCCCTGGGTCTG and 5′-CTCCGCTCACTCTGCAGTC/5′-
ACCTCTGGCACCACAGTAGG). Exons 2–15 were amplified from skeletal
muscle cDNA prepared from an affected and a control horse. cDNAwas amplified
using three overlapping primer pairs (5′-GCACTTTGTCCATGTCCTCA/5′-TT-
TATGGGCACCTGGACTTC, 5′-GAGGCTCAGCACCTACTCAAG/5′-
CATCCCCAGTATCTCCACCA, and 5′-TATGAGCCTTGGGGCTACAC/5′-
CGATGAAGACAGTGAGCGCT).
Glycogen synthase activity in PSSM
Glycogen synthase activity was measured in flash-frozen gluteal muscle
biopsy samples from 17 PSSM and 15 control Quarter Horses (11 PSSM and 12
control without G6P). GS activity was assayed by measuring the incorporation
of glucose from UDP-[U-14C]glucose into glycogen [55]. Twenty milligrams of
frozen muscle was added to homogenate solution (50 mM Tris–acetate, 20 mM
NaF, 2 mM EDTA, 1 mMmercaptoethanol, pH 7.8) at 2% w/v and homogenates
were made using a Potter Elvehjem handheld glass homogenizer. Samples were
centrifuged at 4 °C and 1000 g for 10 min and the supernatant was saved for GS
assay. GS activity was assayed by measuring the incorporation of glucose from
UDP-[U-14C]glucose into glycogen [55] using 6.7 mg/ml deionized rabbit liver
glycogen and 5 mM UDP-glucose (~150 cpm/nmol) [25], both with (maximal
activity) and without 7.2 mM G6P. 14C-labeled glycogen was spotted onto
Whatman No. 5 filter paper and washed in 66% ethanol for 20 min to remove
UDP-[U-14C]glucose. Filters were washed with acetone for 5 min and dried
before being counted in a liquid scintillation counter. A unit of activity was
defined as the amount of enzyme that catalyzed the transfer of 1 µmol of glucose
from UDP-glucose to glycogen in 1 min. Data are expressed as units of GS
activity per milligram of GS protein. The +/- glucose 6-phosphate ratio was
calculated by dividing the activity of GS in the absence of G6P by the activity in
the presence of 7.2 mMG6P [25]. Significant differences in GS activity between
PSSM and control horses were determined using an unpaired t test. Significance
level was set at pb0.05.
GYS1 allele frequency in Quarter Horses
The G-to-A base substitution identified in exon 6 was rapidly genotyped in
PSSM and control horses using a restriction fragment length polymorphism
assay. A 230-bp segment of DNA containing GYS1 exon 6 and the flanking
intronic sequence was amplified by PCR (forward/reverse primer 5′-TGAAA-
CATGGGACCTTCTCC/5′-AGCTGTCCCCTCCCTTAGAC). In horses with-
out the G-to-A polymorphism a single restriction site for the enzyme HpyCH4V
is present in this fragment; in horses with the G-to-A polymorphism a second
restriction site is created. Restriction fragments were resolved using 3% agarose
gel electrophoresis.
GYS1 mutation in diverse horse breeds
Records from muscle biopsy submissions to the University of Minnesota
Neuromuscular Diagnostic Laboratory between January 1996 and January 2007
were reviewed. Submissions from clinical cases and from research horses were
included. Eight hundred twelve PSSM horses from 35 different breeds were
identified from the Neuromuscular Disease Laboratory database. Seven hundred
fifty cases had whole blood or tissue that was available for DNA isolation and
genotyping for theGYS1mutation. Genomic DNAwas isolated from whole blood
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USA) according to the manufacturer's protocol. When whole blood was not
available, genomic DNAwas isolated frommuscle biopsies (frozen or formalized)
using theDNeasy Tissue ExtractionKit (Qiagen, Valencia, CA, USA) according to
the manufacturer's protocol. TheGYS1 genotype of each horse was obtained using
the restriction fragment length polymorphism assay described above.
Haplotype analysis and allele age
Forty-three SNPs were selected for genotyping from a group of 100 well-
characterized SNPs in the 2-Mb region surroundingGYS1. SNPswere genotyped
using the Sequenom platform. Primers were designed using SpectroDESIGNER
software (www.sequenom.com/Seq_genotyping.html). The 43 SNP loci (Sup-
plementary Table 1) were amplified in four multiplex PCRs with 1 to 28 primer
pairs per reaction.
Missing genotypes and haplotype phase were inferred using fastPHASE 1.2
software [26], with the following options included in the algorithm: –H200 to
increase the number of haplotypes sampled from the posterior distribution from a
particular random start of the EM algorithm to 200 to minimize individual error;
–KU30 –KL5 –Ki2 to increase the number of clusters considered (minimum of
5 to maximum of 30 at interval of 2) due to the large number of individuals and
the complexity of the dataset due to the large number of subpopulations; –u to
incorporate subpopulation labels to deal with any deviation from Hardy–
Weinberg equilibrium (HWE) due to subpopulation differences in allele and
haplotypic frequencies; –e to scan for genotype errors across all SNPs. Horses
were grouped into subpopulations by breed. The minimally conserved haplotype
was determined using Haploview 4.0 CR2 [27]. Data from individuals for a given
breed were imported into Haploview as phased haplotypes. Markers were
checked with default parameters of an HWE p value cutoff of p=0.001 and a
minimum minor allele frequency of 0.001. The GYS1 exon 6 G/A SNP
(responsible for the Arg309His mutation) was manually included, despite not
achieving HWE cutoff, which was expected based on the cohort selection.
Haplotype blocks weremanually extended across SNPs on either side of the exon
6 SNP to determine the conserved haplotype around the GYS1 A allele.
Haplotypes that occurred in less than 1% of the cohort were assumed likely to be
due to genotyping error and were not considered.
GYS1 allele age was estimated using the DMLE+ 2.0 software [28]. Due to the
need for an accurate estimation of disease prevalence in the population, only
haplotype data from Quarter Horses, Paint Horses, Belgian, and Percheron horses
were included in the allele age estimation, because these breeds had GYS1 allele
frequency data available from genotyping random hair root samples. Population
growth rates for each of these breeds were determined using numbers for total
registered population and new registries per year obtained from the breed registries.
Weighted averages for allele frequency, population growth rate, and proportion of
disease chromosomes sampled were calculated based on the proportion of total
chromosomes accounted for by each breed (Supplementary Table 2). Weighted
averages were used for parameter estimation in the DMLE+ input. Iterations were
performed over ancestral states andmutation age but not mutation location or allele
frequency.Mean allele age was calculated from the histogram data for the posterior
distribution of the time since the original mutation.
Acknowledgments
Funding for this work was provided by the American Quarter
Horse Association (Genetic Analysis of Glycogen Storage
Disorders in Quarter Horses), the Morris Animal Foundation
(DO5EQ-028 Horse Genomics: Linear Mapping and Microarray
Development), and the National Institutes of Health (NIH T32
RR018719-02 Comparative Medicine and Pathology Training,
M.E. McCue, salary support).
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.ygeno.2008.01.011.References
[1] S.J. Valberg, J.M. MacLeay, J.A. Billstrom, M.A. Hower-Moritz, J.R.
Mickelson, Skeletal muscle metabolic response to exercise in horses with
‘tying-up’ due to polysaccharide storage myopathy, Equine Vet. J. 31
(1999) 43–47.
[2] S.J. Valberg, G.H. Cardinet III, G.P. Carlson, S. DiMauro, Polysaccharide
storage myopathy associated with recurrent exertional rhabdomyolysis in
horses, Neuromuscul. Disord. 2 (1992) 351–359.
[3] S.J. Valberg, C. Geyer, S.A. Sorum, G.H. Cardinet III, Familial basis of
exertional rhabdomyolysis in quarter horse-related breeds, Am. J. Vet. Res.
57 (1996) 286–290.
[4] W.P. Ribeiro, S.J. Valberg, J.D. Pagan, B.E. Gustavsson, The effect of
varying dietary starch and fat content on serum creatine kinase activity and
substrate availability in equine polysaccharide storage myopathy, J. Vet.
Intern. Med. 18 (2004) 887–894.
[5] M.E. McCue, W. Riberio, S.J. Valberg, Prevalence of polysaccharide sto-
rage myopathy in horses with neuromuscular disorders, Equine Vet. J. 36
(2006) 340–344.
[6] A.M. Firshman, S.J. Valberg, J.B. Bender, C.J. Finno, Epidemiologic
characteristics and management of polysaccharide storage myopathy in
quarter horses, Am. J. Vet. Res. 64 (2003) 1319–1327.
[7] F.D. De La Corte, S.J. Valberg, J.M. MacLeay, J.R. Mickelson, Devel-
opmental onset of polysaccharide storage myopathy in 4 quarter horse
foals, J. Vet. Intern. Med. 16 (2002) 581–587.
[8] F.D. De La Corte, S.J. Valberg, J.R. Mickelson, M. Hower-Moritz, Blood
glucose clearance after feeding and exercise in polysaccharide storage
myopathy, Equine Vet. J. Suppl. 30 (1999) 324–328.
[9] F.D. De La Corte, S.J. Valberg, J.M. MacLeay, S.E. Williamson, J.R.
Mickelson, Glucose uptake in horses with polysaccharide storage myo-
pathy, Am. J. Vet. Res. 60 (1999) 458–462.
[10] E.J. Annandale, S.J. Valberg, J.R. Mickelson, E.R. Seaquist, Insulin sen-
sitivity and skeletal muscle glucose transport in horses with equine poly-
saccharide storage myopathy, Neuromuscul. Disord. 14 (2004) 666–674.
[11] E.J. Annandale, S.J. Valberg, B. Essen Gustavsson, The effects of sub-
maximal exercise of adenine nucleotide concentrations in skeletal muscle
fibers of horses with polysaccharide storage myopathy, Am. J. Vet. Res. 66
(2005) 839–845.
[12] A.M. Firshman, J.D. Baird, S.J. Valberg, Prevalences and clinical signs of
polysaccharide storage myopathy and shivers in Belgian draft horses,
J. Am. Vet. Med. Assoc. 227 (2005) 1958–1964.
[13] B.A. Valentine, et al., Incidence of polysaccharide storage myopathy in
draft horse-related breeds: a necropsy study of 37 horses and a mule, J. Vet.
Diagn. Invest 13 (2001) 63–68.
[14] B.A. Valentine, S.P. McDonough, Y.F. Chang, A.J. Vonderchek,
Polysaccharide storage myopathy in Morgan, Arabian, and Standardbred
related horses and Welsh-cross ponies, Vet. Pathol. 37 (2000) 193–196.
[15] B.A. Valentine, B.J. Cooper, Incidence of polysaccharide storage myo-
pathy: necropsy study of 225 horses, Vet. Pathol. 42 (2005) 823–827.
[16] B. Carlstrom, Uber die atiologie und pathogenese der kreuzlahme des
pferdes (Hemaglobinaemia paralytica), Scand. Arch. 62 (1932) 1–62.
[17] M.E. McCue, S.J. Valberg, Estimated prevalence of polysaccharide stor-
age myopathy among overtly healthy quarter horses in the United States,
J. Am. Vet. Med. Assoc. 231 (2007) 746–750.
[18] S.J. Valberg, D. Townsend, J.R. Mickelson, Skeletal muscle glycolytic
capacity and phosphofructokinase regulation in horses with polysaccharide
storage myopathy, Am. J. Vet. Res. 59 (1998) 782–785.
[19] S.J. Valberg, J.M. MacLeay, J.A. Billstrom, M.A. Hower-Moritz, J.R.
Mickelson, Skeletal muscle metabolic response to exercise in horses with
‘tying-up' due to polysaccharide storage myopathy, Equine Vet. J. 31
(1999) 43–47.
[20] P. Dranchak, et al., Biochemical and genetic evaluation of the role of AMP-
activated protein kinase in polysaccharide storage myopathy in Quarter
Horses, Am. J. Vet. Res. 68 (10) (2007) 1079–1084.
[21] B. Candice, et al., A high-resolution physical map of equine homologs
of HSA19 shows divergent evolution compared with other mammals,
Mamm. Genome V16 (2005) 631–649.
[22] P.J. Roach, Glycogen and itsmetabolism, Curr.Mol.Med. 2 (2002) 101–120.
466 M.E. McCue et al. / Genomics 91 (2008) 458–466[23] M.M.McGrane, Carbohydrate metabolism synthesis and oxidation, in:M.H.
Stipanuk (Ed.), Biochemical and Physiological Aspects of Human Nutrition,
Saunders, Ithaca, NY, 2000, pp. 158–210.
[24] A.V. Skurat, H.L. Peng, H.Y. Chang, J.F. Cannon, P.J. Roach, Rate-
determining steps in the biosynthesis of glycogen in COS cells, Arch.
Biochem. Biophys. 328 (1996) 283–288.
[25] B.A. Pederson, C. Cheng, W.A. Wilson, P.J. Roach, Regulation of gly-
cogen synthase: identification of residues involved in regulation by the
allosteric ligand glucose-6-P and by phosphorylation, J. Biol. Chem. 275
(2000) 27753–27761.
[26] P. Scheet, M. Stephens, A fast and flexible statistical model for large-scale
population genotype data: applications to inferring missing genotypes and
haplotypic phase, Am. J. Hum. Genet. 78 (2006) 629–644.
[27] J.C. Barrett, B. Fry, J. Maller, M.J. Daly, Haploview: analysis and visua-
lization of LD and haplotype maps, Bioinformatics 21 (2005) 263–265.
[28] B. Rannala, J.P. Reeve, Joint Bayesian estimation of mutation location and
age using linkage disequilibrium, Pac. Symp. Biocomput. (2003) 526–534.
[29] L. Ollivier, Situation and justification of the conservation of animal
genetics resources in Europe, Naturzale 14 (1999) 17–27.
[30] J. Manchester, A.V. Skurat, P. Roach, S.D. Hauschka, J.C. Lawrence Jr.,
Increased glycogen accumulation in transgenic mice overexpressing gly-
cogen synthase in skeletal muscle, Proc. Natl. Acad. Sci. U. S. A. 93
(1996) 10707–10711.
[31] N. Raben, et al., Surprises of genetic engineering: a possible model of
polyglucosan body disease, Neurology 56 (2001) 1739–1745.
[32] B.A. Pederson, et al., Mice with elevated muscle glycogen stores do not
have improved exercise performance, Biochem. Biophys. Res. Commun.
331 (2005) 491–496.
[33] A.V. Skurat, Y. Wang, P.J. Roach, Rabbit skeletal muscle glycogen
synthase expressed in COS cells: identification of regulatory phosphoryla-
tion sites, J. Biol. Chem. 269 (1994) 25534–25542.
[34] C. Anderson, K. Tatchell, Hyperactive glycogen synthase mutants of
Saccharomyces cerevisiae suppress the glc7-1 protein phosphatase mutant,
J. Bacteriol. 183 (2001) 821–829.
[35] K. Furukawa, M. Tagaya, K. Tanizawa, T. Fukui, Identification of Lys277
at the active site of Escherichia coli glycogen synthase: application of
affinity labeling combined with site-directed mutagenesis, J. Biol. Chem.
269 (1994) 868–871.
[36] A. Buschiazzo, et al., Crystal structure of glycogen synthase: homologous
enzymes catalyze glycogen synthesis and degradation, EMBO J. 23 (2004)
3196–3205.
[37] K. Furukawa, M. Tagaya, M. Inouye, J. Preiss, T. Fukui, Identification of
lysine 15 at the active site in Escherichia coli glycogen synthase: con-
servation of Lys-X-Gly-Gly sequence in the bacterial and mammalian en-
zymes, J. Biol. Chem. 265 (1990) 2086–2090.
[38] A.M. Mahrenholz, Y.H. Wang, P.J. Roach, Catalytic site of rabbit glycogen
synthase isozymes: identification of an active site lysine close to the amino
terminus of the subunit, J. Biol. Chem. 263 (1988) 10561–10567.[39] K. Furukawa, M. Tagaya, K. Tanizawa, T. Fukui, Role of the conserved
Lys-X-Gly-Gly sequence at the ADP-glucose-binding site in Escherichia
coli glycogen synthase, J. Biol. Chem. 268 (1993) 23837–23842.
[40] A. Yep, M.A. Ballicora, J. Preiss, The active site of the Escherichia
coli glycogen synthase is similar to the active site of retaining GT-B
glycosyltransferases, Biochem. Biophys. Res. Commun. 316 (2004)
960–966.
[41] A. Yep, M.A. Ballicora, M.N. Sivak, J. Preiss, Identification and char-
acterization of a critical region in the glycogen synthase from Escherichia
coli, J. Biol. Chem. 279 (2004) 8359–8367.
[42] A. Yep, M.A. Ballicora, J. Preiss, The ADP-glucose binding site of the
Escherichia coli glycogen synthase, Arch. Biochem. Biophys. 453 (2006)
188–196.
[43] M. Tagaya, K. Nakano, T. Fukui, A new affinity labeling reagent for
the active site of glycogen synthase: uridine diphosphopyridoxal, J. Biol.
Chem. 260 (1985) 6670–6676.
[44] E. Cid, R.R. Gomis, R.A. Geremia, J.J. Guinovart, J.C. Ferrer,
Identification of two essential glutamic acid residues in glycogen synthase,
J. Biol. Chem. 275 (2000) 33614–33621.
[45] B.A. Pederson, W.A. Wilson, P.J. Roach, Glycogen synthase sensitivity to
glucose-6-P is important for controlling glycogen accumulation in Sac-
charomyces cerevisiae, J. Biol. Chem. 279 (2004) 13764–13768.
[46] I. Hanashiro, P.J. Roach, Mutations of muscle glycogen synthase that
disable activation by glucose 6-phosphate, Arch. Biochem. Biophys. 397
(2002) 286–292.
[47] S. DiMauro, A.P. Hayes, S. Tsujino, Nonlysosmal glycogenoses, in: A.G.
Engel, C. Franzini-Armstrong (Eds.), Myology, McGraw–Hill, New York,
2004, pp. 1535–1558.
[48] G. Kollberg, et al., Cardiomyopathy and exercise intolerance in muscle
glycogen storage disease 0, N. Engl. J. Med. 357 (2007) 1507–1514.
[49] S. DiMauro, S. Tsujino, S. Shanske, L.P. Rowland, Biochemistry and
molecular genetics of human glycogenoses: an overview, Muscle Nerve 3
(1995) S10–S17.
[50] M.E. McCue, W.P. Ribeiro, S.J. Valberg, The prevalence of polysaccharide
storage myopathy in quarter horses, J. Vet. Intern. Med. 20 (2006) 710.
[51] P. Heutink, B.A. Oostra, Gene finding in genetically isolated populations,
Hum. Mol. Genet. 11 (2002) 2507–2515.
[52] J. Ott, Nonparametric Methods, Analysis of Human Genetic Linkage, John
Hopkins Univ. Press, Baltimore, 1999, pp. 272–296.
[53] S. Purcell, S.S. Cherny, P.C. Sham, Genetic Power Calculator: design of
linkage and association genetic mapping studies of complex traits, Bio-
informatics 19 (2003) 149–150.
[54] N.H. Chapman, E.M. Wijsman, Genome screens using linkage disequili-
brium tests: optimal marker characteristics and feasibility, Am. J. Hum.
Genet. 63 (1998) 1872–1885.
[55] J.A. Thomas, K.K. Schlender, J. Larner, A rapid filter paper assay for
UDPglucose–glycogen glucosyltransferase including an improved bio-
synthesis of UDP-14C-glucose, Anal. Biochem. 25 (1968) 486–499.
